GENOMIC HEALTH INC (GHDX) Stock News
NASDAQ:GHDX - Nasdaq -
GHDX Latest News, Press Relases and Analysis
Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)
Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Mentions: EXAS
Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences
Mentions: EXAS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Genomic Health (NASDAQ: GHDX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx Pharmaceutical (RARE – Research Report) and Genomic Health (GHDX – Research Report). Ultragenyx Pharmaceutical (RARE) J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Ultragenyx Pharmaceutical yesterday and set a price target of $75.00. The company’s shares closed
Shenandoah Telecommunications Set to Join S&P SmallCap 600
Shentel set to join SmallCap 600
Shenandoah Telecommunications (NASDAQ:SHEN) is moving into the S&P SmallCap 600. It's there to replace Genomic Health (NASDAQ:GHDX), set to be acquired by Exact Sciences. The move is effective pr
Mentions: SHEN
Genomic Health reported EPS beat of $0.10
Genomic Health (NASDAQ:GHDX): Q3 GAAP EPS of $0.48 beats by $0.10.Revenue of $114.36M (+12.9% Y/Y) beats by $2.09M.Reported on Oct. 30, 2019.Press Release
Best & Worst Performing Mid Cap Stocks for October 30, 2019
PCG – PCG leads the way today as the best performing mid cap stock, closing up 22.07%.
ENPH, MAT, CHRW and AJRD among after hour movers
Gainers: MAT +19.3%. GDOT +16.1%. PSMT +14.3%. IPHI +9.3%. UIS +8.9%.Losers: ENPH -14.5%. ARAY -8.3%. AJRD -8.2%GHDX -5.5%. CHRW -5.3%.
Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?
Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Moore Kuehn, PLLC Encourages Genomic Health, Inc. and Carbonite, Inc. Investors to Contact Firm
25 Stocks Moving in Tuesday's Pre-Market Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares rose 41.2% to $142.03 in pre-market trading after the company reported topline results from its MOXle registrational trial...
Here's Why Genetic Testing Stocks Tumbled in September
Most stocks in the industry cooled off from all-time highs. Will they keep sliding?
3 Cancer-Fighting Drug Stocks to Buy Right Now
These drug stocks are among the best to buy now because each is making progress in the fight against cancer. Here's what you should know about each.
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Genomic Health, Inc. (GHDX)
Stocks & ETF to Invest in Healthcare Robotics and Innovation
HTEC is poised to benefit from rapid advances in health-care technology
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
Stocks & ETF to Invest in Healthcare Robotics and Innovation
HTEC is poised to benefit from rapid advances in health-care technology.
10 Excellent Stocks to Watch for 2020 and Beyond
EXACT Sciences, Alphabet and Square are just some of the best stocks to watch for 2020, even if they're not quite ready to be bought yet.
Why Is Genomic Health (GHDX) Down 0.5% Since Last Earnings Report?
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health Test to Guide Chemo Per New Breast Cancer Rule
This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.
A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis
What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.